OncoMatch/Clinical Trials/NCT06971744
Autophagy Maintenance (AUTOMAIN)
Is NCT06971744 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Hydroxychloroquine and Nelfinavir for ovarian cancer.
Treatment: Hydroxychloroquine · Nelfinavir · Bevacizumab — This is a single-institution, single-arm study with a safety lead-in to determine if previously established safe doses of autophagy drugs, hydroxychloroquine (HCQ) and nelfinavir mesylate (NFV) will benefit ovarian cancer patients in a maintenance setting. Patients will receive the two study drugs HCQ and NFV in combination with maintenance bevacizumab.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Ovarian Cancer
Biomarker criteria
Required: BRCA1 mutation status known (germline or somatic)
germline panel testing with at least BRCA 1/2 mutation status known and/or somatic tumor next generation sequencing with homologous recombination deficiency (HRD) testing and/or loss of heterozygosity (LOH) known
Required: BRCA2 mutation status known (germline or somatic)
germline panel testing with at least BRCA 1/2 mutation status known and/or somatic tumor next generation sequencing with homologous recombination deficiency (HRD) testing and/or loss of heterozygosity (LOH) known
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy — first recurrence
Participants must have had a 6-month disease-free progression since last platinum chemotherapy to be considered platinum sensitive.
Must have received: bevacizumab (bevacizumab) — during chemotherapy for first recurrence
Participants must have received at least 3-courses of bevacizumab during chemotherapy and have a plan to continue maintenance bevacizumab therapy.
Cannot have received: PARP inhibitor maintenance
Exception: patients will be allowed if previously did not tolerate PARP and opt against PARP maintenance
Platinum-sensitive patients that are candidates for PARP inhibitor maintenance, patients will be allowed if previously did not tolerate PARP and opt against PARP maintenance
Lab requirements
Blood counts
ANC ≥ 1,000 cells/mm3; Platelet count ≥ 75,000 cells/mm3; Hemoglobin ≥ 9 g/dL (recent transfusion allowed, must be ≥ 7 days before C1D1)
Kidney function
CrCl ≥35 mL/min, Cockgroft-Gault formula.
Liver function
Bilirubin ≤ 1.5x ULN and AST/ALT ≤ 3x ULN. Gilbert's syndrome: total bilirubin < 3x ULN and direct bilirubin within normal limits.
Cardiac function
QT interval <450 ms on screening ECG; adequately controlled blood pressure (<160/100 mm Hg)
Bilirubin ≤ 1.5 times the upper limit of normal (ULN) and AST / ALT ≤ 3 times ULN. Subjects with Gilbert's syndrome may be included if the total bilirubin is < 3 times ULN and the direct bilirubin is within normal limits. CrCl ≥35 mL/min, according to the Cockgroft-Gault formula. Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3. Platelet count ≥ 75,000 cells / mm3. Hemoglobin ≥ 9 g/ dL, recent transfusion is allowed, though must be ≥ 7 days C1D1 of investigational agents. Adequately controlled blood pressure (<160 mm Hg/100 mm Hg) as determined by the treating investigator. Patients must have a QT interval of <450 ms on screening upon ECG.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Medical University of South Carolina · Charleston, South Carolina
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06971744 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior PARP inhibitor maintenance disqualifies patients from enrollment.
Does this trial require BRCA1?
Yes, BRCA1 mutation status known (germline or somatic) is a required biomarker for enrollment.
Does this trial require BRCA2?
Yes, BRCA2 mutation status known (germline or somatic) is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages